Sanofi’s pipeline for achondroplasia, SAR442501 (Anti-FGFR3 antibody) falls under their rare disease therapeutic area. Currently, this pipeline is in Phase 1 and the expected submission timeline is not yet available.


According to GlobalData, Phase I drugs for achondroplasia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SAR-442501 LoA Report. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.